Oral tributyrin treatment affects short-chain fatty acid transport, mucosal health, and microbiome in a mouse model of inflammatory diarrhea

Zhenghao Ye(Medizinische Hochschule Hannover), Ursula Seidler(Medizinische Hochschule Hannover), Archana Kini(Medizinische Hochschule Hannover), Katerina Nikolovska(Medizinische Hochschule Hannover), Sabrina Woltemate(Medizinische Hochschule Hannover), Marius Vital(Medizinische Hochschule Hannover), Qinghai Tan(Tongji Hospital)
The Journal of Nutritional Biochemistry
January 25, 2025
10.1016/j.jnutbio.2025.109847
Cited by 5

Related Papers

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
|New England Journal of Medicine|2016|1.8k
Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity
|PLoS ONE|2007|478
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial
|The Lancet|2021|452
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
|The Lancet|2017|449
Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase II
|Science|1996|409